Screener
Collegium Pharmaceutical, Inc. COLL Symproic and other — Finite-Lived Intangible Assets, Net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The source filing: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 7:34 AM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-011992
| Line item | As of December 31, 2025 / Cost | As of December 31, 2025 / Accumulated Amortization | As of December 31, 2025 / Carrying Amount | As of December 31, 2024 / Cost | As of December 31, 2024 / Accumulated Amortization | As of December 31, 2024 / Carrying Amount |
|---|---|---|---|---|---|---|
| Jornay PM | $635,000 | $(111,072) | $523,928 | $635,000 | $(27,242) | $607,758 |
| Belbuca | 360,000 | (284,607) | 75,393 | 360,000 | (209,214) | 150,786 |
| Nucynta Products (1) | 521,170 | (493,478) | 27,692 | 521,170 | (438,094) | 83,076 |
| Symproic | 70,000 | (27,503) | 42,497 | 70,000 | (20,218) | 49,782 |
| Total intangibles | $1,586,170 | $(916,660) | $669,510 | $1,586,170 | $(694,768) | $891,402 |
Item 16. Form 10-K Summary
FAQ
- What is Collegium Pharmaceutical, Inc.'s symproic and other — finite-lived intangible assets, net?
- Collegium Pharmaceutical, Inc. (COLL) reported symproic and other — finite-lived intangible assets, net of $42.5M in Q4 2025.
- What does symproic and other — finite-lived intangible assets, net mean?
- The carrying value of intangible assets associated with the Symproic segment, calculated as the gross book value minus accumulated amortization. This represents the remaining unamortized economic value of the product rights or intellectual property on the balance sheet.
Ask your AI about Collegium Pharmaceutical, Inc.'s symproic and other — finite-lived intangible assets, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude